18F-FDG PET/CT用于III期Merkel细胞癌治疗后监测影像
本回顾性研究纳入61例临床无症状的III期Merkel细胞癌(MCC)患者,在根治性治疗后行18F-FDG PET/CT监测。PET/CT在33%(20/61)患者中检出未预料复发,病灶基于的灵敏度、特异度和准确率分别为92%、93%、93%。治疗后1年内PET/CT阳性者总生存较差(P<0.0001),且SUVmax和阳性病灶数独立与死亡风险相关。
要点
- 18F-FDG PET/CT在33%无症状III期MCC患者中检出未预料复发。
- 治疗后1年内PET/CT阳性者总生存显著较差(P<0.0001)。
- SUVmax每增加1单位死亡风险HR=1.17(P=0.006)。
核心结论
- 根治性治疗后监测18F-FDG PET/CT可检出未预料复发并具有预后价值。
- 建议在根治性治疗后6个月内纳入18F-FDG PET/CT用于监测和早期发现复发。
研究设计与样本
- 回顾性研究纳入61例连续临床无症状的III期MCC患者,根治性治疗后行监测18F-FDG PET/CT,中位随访4.8年。
- PET/CT结果与病理或临床/影像随访 correlated。
主要发现
- 18F-FDG PET/CT在33%(20/61)患者中检出未预料复发。
- 病灶基于的灵敏度、特异度和准确率分别为92%、93%、93%。
- 恶性与良性病灶的平均±SD SUV分别为7.5±3.9和3.8±2.0。
- 12/61例患者以未知远处转移为首发复发部位。
- 治疗后1年内PET/CT阳性者总生存相对较差(P<0.0001)。
关键数值与推荐
- 18F-FDG PET/CT病灶基于灵敏度92%、特异度93%、准确率93%。
- 恶性病灶平均SUV 7.5±3.9,良性病灶平均SUV 3.8±2.0。
- SUVmax每增加1单位死亡风险HR=1.17(P=0.006)。
- PET/CT阳性病灶每增加1个死亡风险HR=1.60(P<0.001)。
临床怎么用
- 对III期MCC根治性治疗后临床无症状患者,可考虑在6个月内行18F-FDG PET/CT监测以早期发现复发。
- PET/CT阳性(尤其治疗后1年内)提示预后较差,SUVmax和阳性病灶数可辅助风险分层。
局限性
- 本研究为回顾性设计。
- 样本量有限(61例)。
- 作者指出数据需进一步研究评估预后意义。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to investigate the diagnostic and prognostic value of 18F-FDG PET/CT for surveillance imaging in patients treated for stage III Merkel cell carcinoma (MCC). Methods: This retrospective study included 61 consecutive stage III MCC patients who were clinically asymptomatic and underwent surveillance 18F-FDG PET/CT. Findings were correlated with either pathology or clinical/imaging follow-up. The median follow-up period was 4.8 y. Statistical analyses were performed. Results:18F-FDG PET/CT detected unsuspected recurrences in 33% patients (20/61) with lesion-based sensitivity, specificity, and accuracy of 92%, 93%, and 93%, respectively. The mean ± SD SUV for malignant and benign lesions was 7.5 ± 3.9 and 3.8 ± 2.0, respectively. Unknown distant metastases, as first recurrence site, were noted in 12 of 61 patients. Those with positive disease on 18F-FDG PET/CT within 1 y of definitive treatment had relatively worse overall survival (P < 0.0001). After adjustment on stage, risk of death increased with a higher SUVmax (hazard ratio for 1 unit = 1.17; P = 0.006) and with a higher number of positive lesions on 18F-FDG PET/CT (hazard ratio for 1 additional lesion = 1.60; P < 0.001). Conclusion: Postdefinitive treatment surveillance 18F-FDG PET/CT scanning detects unsuspected recurrences and has prognostic value. Inclusion of 18F-FDG PET/CT within the first 6 mo after definitive treatment would be appropriate for surveillance and early detection of recurrence. Our data merit further studies to evaluate the prognostic implications.
引用
- Mahajan S, Barker CA, Mauguen A, et al. 18F-FDG PET/CT for Posttreatment Surveillance Imaging of Patients with Stage III Merkel Cell Carcinoma. J Nucl Med. 2021. PMID: 34620729. doi:10.2967/jnumed.121.262882
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。